Efficacy and tolerability of once-daily budesonide/formoterol pressurized metered-dose inhaler in adults and adolescents with asthma previously stable with twice-daily budesonide/formoterol dosing

Annals of Allergy, Asthma and Immunology

Volumn 103, Issue 1, 2009, Pages 62-72

  Kerwin, Edward M ^a   Oppenheimer, John J ^b   LaForce, Craig ^c   Parasuraman, Bhash ^d   Miller, Christopher J ^d   O'Dowd, Liza ^d   Goldman, Mitchell ^d  

^a Clinical Research Institute of Southern Oregon   (United States)

^b Pulmonary and Allergy Associates PA   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; SALBUTAMOL;

ADOLESCENT; ADOLESCENT DISEASE; ADULT; ADULT DISEASE; AGED; ANXIETY; AROUSAL; ARTICLE; ASTHMA; BEDTIME DOSAGE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHONIA; FEMALE; FORCED EXPIRATORY VOLUME; GASTROESOPHAGEAL REFLUX; HEADACHE; HUMAN; IRON DEFICIENCY ANEMIA; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; MULTICENTER STUDY; OUTCOME ASSESSMENT; PANCREATITIS; PATIENT COMPLIANCE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SCHOOL CHILD; SIDE EFFECT; SORE THROAT; SYMPTOM; THORAX PAIN; THRUSH; THYROID TUMOR; TREATMENT DURATION; VIRUS INFECTION;

EID: 67650354583     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60145-7     Document Type: Article

References (19)

1. National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program Expert Panel Report 3: guidelines for the diagnosis and management of asthma. Full report 2007. http:// www.nhlbi.nih.gov/guidelines/ asthma/asthgdln.htm. Accessed September 19, 2007.
2. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Revised 2006. http://www.ginasthma.org/ Guidelineitem.asp??l1=2&l2=1&intId=60. Accessed May 29, 2007.
3. Buhl R, Creemers JPHM, Vondra V, Martelli NA, Naya IP, Ekström T. Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. Respir Med. 2003;97:323-330. (Pubitemid 36410602)
4. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis. 1987;136:225-244.
5. Juniper EF, Buist AS, Cox FM, Ferrie PJ, King DR. Validation of a standardized version of the asthma quality of life questionnaire. Chest. 1999b;115:1265-1270. (Pubitemid 29230632)
6. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14:902-907. (Pubitemid 29519356)
7. Murphy K, Nelson H, Parasuraman B, Boggs R, Miller C, O'Dowd L. The effect of budesonide and formoterol in one pressurized metereddose inhaler on patient-reported outcomes in adults with mild-tomoderate persistent asthma. Curr Med Res Opin. 2008;24:879-894.
8. Corren J, Korenblat PE, Miller CJ, O'Brien CD, Mezzanotte WS. Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metereddose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma. Clin Ther. 2007;29:823-843. (Pubitemid 47225183)
9. Noonan M, Rosenwasser LJ, Martin P, O'Brien CD, O'Dowd L. Efficacy and safety of budesonide and formoterol in one pressurised metered- dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial. Drugs. 2006;66:2235-2254. (Pubitemid 44878530)
10. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol. 1994;47:81-87. (Pubitemid 24034293)
11. Juniper EF, Svensson K, Mörk A-C, Ståhl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med. 2005;99:553-558. (Pubitemid 40468501)
12. Masoli M, Williams M, Weatherall M, Beasley R. The 24h duration of bronchodilator action of the budesonide/formoterol combination inhaler. Respir Med. 2006;100:20-25. (Pubitemid 43033375)
13. Lötvall J, Langley S, Woodcock A. Inhaled steroid/long-acting β2 agonist combination products provide 24 hours improvement in lung function in adult asthmatic patients. Respir Res. 2006;7:110. (Pubitemid 44419886)
14. Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lötvall J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J. 1997;10: 2484-2489. (Pubitemid 28048620)
15. Jones AH, Langdon CG, Lee PS, et al. Pulmicort Turbohaler once daily as initial prophylactic therapy for asthma. Respir Med. 1994;88: 293-299. (Pubitemid 24157704)
16. Pincus DJ, Humeston TR, Martin RJ. Further studies on the chronotherapy of asthma with inhaled steroids: the effect of dosage timing on drug efficacy. J Allergy Clin Immunol. 1997;100:771-774. (Pubitemid 28298995)
17. Krishnan JA, Riekert KA, McCoy JV, et al. Corticosteroid use after hospital discharge among high-risk adults with asthma. Am J Respir Crit Care Med. 2004;170:1281-1285. (Pubitemid 39657191)
18. Stoloff SW, Stempel DA, Meyer J, Stanford RH, Carranza Rosenzweig JR. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol. 2004;113:245-251. (Pubitemid 38210545)
19. Halm EA, Mora P, Leventhal H. No symptoms, no asthma: the acute episodic disease belief is associated with poor self-management among inner-city adults with persistent asthma. Chest. 2006;129:573-580.